This case describes the reorganization of drug discovery at GlaxoSmithKline (GSK) following the formation of GSK from the merger of Glaxo Wellcome and SmithKline Beecham. This reorganization placed nearly 2‚000 research scientists into six centers of excellence in drug discovery (CEDD). Each CEDD focused on a small set of therapeutic areas and possessed decision rights over the progression of pharmaceutical compounds through the early stages of development. It addresses issues about the benefits
Premium Clinical trial Drug discovery Pharmaceutical industry
one considers the current and then state of the pharmaceutical industry it becomes apparent that there was in fact the need for a merger or other form of change in order to remain competitive. Following the 1997 expiry on the patent of blockbuster drug Zantac‚ the company merged with Wellcome and reaped rewards through marketing existing products. However‚ due to a shortage of new products in the pipeline‚ the firm began to experience dangerously low profit margins. Thus it can be argued that Glaxo
Premium Pharmaceutical industry
proposal for the centers of excellence in drug discovery (CEDD)? What are its strengths and weaknesses relative to other potential organizational structures for R&D? Overview: Yamada reorganization of drug discovery at GlaxoSmithKline (GSK) following a merger to combat bureaucracy in decision making‚ approval‚ and authorization. This reorganization was necessary for the continued success of the company. Often the process for drug discovery and market is a slow and tedious process which
Premium Drug discovery Pharmacology New product development
KPIs for Drug Discovery STRATEGIC IMPERATIVES • • Product Quality Benchmarking among the competitors CRITICAL SUCCESS FACTORS • • • Sustainable quality High Standards Optimal Pricing Strategy KEY PERFORMANCE INDICATORS • • • • • Pioneers in Quality and Standards • • Positive results of Quality
Premium Customer service Customer
creation‚ discovery‚ development‚ manufacture and marketing of pharmaceutical and consumer health related products. The company operated in two segments: Pharmaceuticals (Prescription pharmaceuticals and vaccines)‚ and Consumer Healthcare. STRATEGIC BUSINESS UNIT – PHARMACEUTICALS MANUFACTURING AND MARKETING STRATEGIC GROUP FOR THE SBU – CONTRACT MANUFACTURING Company Information & Market Analysis GlaxoSmithKline PLC (NYSE:GSK)‚ formed through the merger of British drug makers Glaxo
Premium Pharmaceutical industry
COMPANY OVERVIEW GlaxoSmithKline (GSK) is one of the world’s leading research-based pharmaceutical and healthcare companies. The company is engaged in the discovery‚ development‚ manufacturing and marketing of pharmaceutical and consumer health-related products. The company primarily operates in 120 countries and its products are sold in more than 150 countries. GSK is headquartered in Brentford‚ the UK and employed 99‚913 people as of December 31‚ 2009. The company recorded revenues of £28‚368
Premium
history. This project looked at GlaxoSmithKline in Dungarvan‚ Co. Waterford. GSK has been manufacturing in Dungarvan since 1981 and has two manufacturing sites there. The first is the Oral care facility which was set up in 1981 and the second is the over the counter medicine site which was set up in 1987. Many of the company’s flagship brands are produced in Dungarvan including Panadol‚ Polygrip and NiQuitn. According to the GSK Website “Products produced in Dungarvan are exported to more than 70 countries
Premium
GlaxoSmithKline (GSK) is one of the largest and most profitable pharmaceutical companies in the world. This conglomerate is the product of multiple mergers of some of the leading companies in the industry. It was created in 2000 and at the time this case was written‚ had a market capitalization of $193.5 billion. The company’s most recent focus is on emerging markets‚ vaccines and consumer healthcare. When Sir Andrew Witty took over as CEO in 2008‚ he implemented a significant restructuring program
Premium Vaccine Pharmacology Pharmaceutical industry
EC229 Economics of Strategy Introduction 1. GlaxoSmithKline (GSK) is a global healthcare company specialized in the research‚ development‚ manufacturing and marketing of pharmaceutical and consumer health-related products. The company has operations in 120 countries‚ with products being sold in over 150 countries. (Description) 2. As a dominant player in the pharmaceutical industry‚ GSK operates in an oligopolistic market. It is highly cash generative‚ with increased sales growth and shareholder
Premium Costs Economics Oligopoly
What are the implications of personal genomes for drug discovery and development ? In the past decade‚ increasing amounts of dollars have been spent on drug development yet the amount of new drugs entering the market per year remains the same. Furthermore with 200 billion dollars of patents expiring in the past four years (Witty‚ 2010)‚ innovative pharmaceutical companies will need to look at new approaches to discover drugs. With the human genome being sequenced in 2003‚ a new field of science
Premium Pharmacology Genetics Genome